Search
Nilvadipine
go.drugbank.com/drugs/DB06712ApprovedNilvadipine is a calcium channel blocker (CCB) for the treatment of hypertension.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 InhibitorsProducts: ESCOR FORTE 16MG RET KAPRivaroxaban
go.drugbank.com/drugs/DB06228ApprovedInvestigationalRivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. … Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, 2011.
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesProducts: Mar-rivaroxaban, Ixobran 15 (Rivaroxaban Tablet Ph Eur 15mg)Aloe vera flower
go.drugbank.com/drugs/DB14254ApprovedIt is not an approved drug.
Synonyms: Li Hui HuaCiclesonide
go.drugbank.com/drugs/DB01410ApprovedInvestigationalCiclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco.
Categories: Drugs for Obstructive Airway Diseases, Cytochrome P-450 SubstratesProducts: ALVESCO 160UG 60 HUB, ALVESCO 80UG 120 HUBSatralizumab
go.drugbank.com/drugs/DB15762ApprovedInvestigationalmanner[A218551] - this allows satralizumab to bind an IL-6 receptor until it reaches an endosome, after which the drug may dissociate from the receptor and move back into the plasma to act again. … Satralizumab was first approved for use in Canada in June 2020 for the treatment of AQP4 antibody-positive patients with NMOSD.
Categories: Interleukin-6 Receptor AntagonistSynonyms: Humanised anti-IL-6 receptor monoclonal antibodyCefaclor
go.drugbank.com/drugs/DB00833ApprovedInvestigationalSemisynthetic, broad-spectrum antibiotic derivative of cephalexin.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseProducts: CECLOR 12 HR, CEFACLOR RATIO 500MG KAPInsulin glargine
go.drugbank.com/drugs/DB00047ApprovedInvestigationalThe resulting protein is soluble at pH 4 and forms microprecipitates at physiological pH 7.4 allowing for the slow release of small amounts of insulin glargine, giving the drug a long duration of action … Absorption of glucose into cells allows for its transformation into glycogen or fat for storage.
Mixtures: Soliqua SoloStar 100units/mL+33mcg/mL solution for injection in a pre-filled pen, SOLIQUA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100UNITS/ML + 50MCG/MLCategories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme InducersProthrombin
go.drugbank.com/drugs/DB11311ApprovedInvestigationalProthrombin Complex Concentrate (Human), is indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with
Mixtures: BERIPLEX P/N 500 POWDER FOR SOLUTION FOR INJECTION, Beriplex P/N 500 I.E. Pulver und Lösungsmittel zur Herstellung einer InjektionslösungInfliximab
go.drugbank.com/drugs/DB00065ApprovedInvestigationalalternative first-line therapies for that disorder [FDA Label]. … By binding to both the soluble subunit and the membrane-bound precursor of TNF-α [A106], infliximab disrupts the interaction of TNF-α with its receptors and may also cause lysis of cells that produce TNF-α
Categories: Biologics for Rheumatoid Arthritis Treatment, Tumor Necrosis Factor Receptor Blocking ActivityProducts: REMICADE 100MG PUL HER INF, POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/VIALLoratadine
go.drugbank.com/drugs/DB00455ApprovedInvestigational[A176435] A lack of sedative and CNS adverse effects make loratadine, along with other second generation antihistamines, preferable over their 1st generation counterparts in many clinical situations.
Mixtures: PAX MAX DIA, LORACERT- P JARABECategories: Antihistamines for Systemic Use, P-glycoprotein inhibitors